213 related articles for article (PubMed ID: 37668079)
41. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
[TBL] [Abstract][Full Text] [Related]
42. Gene expression changes in cervical squamous cancers following neoadjuvant interventional chemoembolization.
Chen Y; Hou Y; Yang Y; Pan M; Wang J; Wang W; Zuo Y; Cong J; Wang X; Mu N; Zhang C; Gong B; Hou J; Wang S; Xu L
Clin Chim Acta; 2019 Jun; 493():79-86. PubMed ID: 30772336
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Significance of Nuclear Factor Kappa B Expression in Locally Advanced Cervical Cancer Patients Treated Definitively With Concurrent Chemoradiation.
Altoos B; Small C; Dalal P; Attieh D; El Achy S; Parimi V; Wei JJ; Helenowski I; Donnelly ED; Strauss J; Small W; Refaat T
Am J Clin Oncol; 2020 Jan; 43(1):47-51. PubMed ID: 31693509
[TBL] [Abstract][Full Text] [Related]
44. High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma.
Zhang W; He W; Shi Y; Gu H; Li M; Liu Z; Feng Y; Zheng N; Xie C; Zhang Y
PLoS One; 2016; 11(12):e0167449. PubMed ID: 27941992
[TBL] [Abstract][Full Text] [Related]
45. Identification of Significant Gene Signatures and Prognostic Biomarkers for Patients With Cervical Cancer by Integrated Bioinformatic Methods.
Li X; Tian R; Gao H; Yan F; Ying L; Yang Y; Yang P; Gao Y
Technol Cancer Res Treat; 2018 Jan; 17():1533033818767455. PubMed ID: 29642758
[TBL] [Abstract][Full Text] [Related]
46. Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
DeBoer RJ; Umutoni V; Bazzett-Matabele L; Katznelson E; Nguyen C; Umwizerwa A; Bigirimana JB; Paciorek A; Nsabimana N; Ruhangaza D; Ntasumbumuyange D; Shulman LN; Triedman SA; Shyirambere C
Gynecol Oncol; 2022 Feb; 164(2):370-378. PubMed ID: 34916066
[TBL] [Abstract][Full Text] [Related]
47. PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery.
Testa AC; Moro F; Pasciuto T; Moruzzi MC; Di Legge A; Fuoco G; Autorino R; Collarino A; Gui B; Zannoni GF; Gambacorta A; Miccò M; Rufini V; Scambia G; Ferrandina G
Ultrasound Obstet Gynecol; 2018 Jul; 52(1):110-118. PubMed ID: 29119649
[TBL] [Abstract][Full Text] [Related]
48. Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.
Guo L; Wu H; Zhu J; Zhang C; Ma J; Lan J; Xie X
Life Sci; 2015 Dec; 143():217-24. PubMed ID: 26585822
[TBL] [Abstract][Full Text] [Related]
49. The value of perfusion CT in predicting the short-term response to synchronous radiochemotherapy for cervical squamous cancer.
Li XS; Fan HX; Zhu HX; Song YL; Zhou CW
Eur Radiol; 2012 Mar; 22(3):617-24. PubMed ID: 21960157
[TBL] [Abstract][Full Text] [Related]
50. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
[TBL] [Abstract][Full Text] [Related]
51. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
[TBL] [Abstract][Full Text] [Related]
52. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
[TBL] [Abstract][Full Text] [Related]
53. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
[TBL] [Abstract][Full Text] [Related]
54. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome.
Klopp AH; Jhingran A; Ramdas L; Story MD; Broadus RR; Lu KH; Eifel PJ; Buchholz TA
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):226-36. PubMed ID: 18406887
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery.
Miller H; Matsuo K; Roman LD; Yessaian AA; Pham HQ; Hom M; Castaneda A; Pham A; Ragab O; Muderspach L; Ciccone M; Brunette LL
Radiat Oncol; 2021 Jun; 16(1):123. PubMed ID: 34187504
[TBL] [Abstract][Full Text] [Related]
56. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
57. Changes in cervical cancer FDG uptake during chemoradiation and association with response.
Kidd EA; Thomas M; Siegel BA; Dehdashti F; Grigsby PW
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):116-22. PubMed ID: 22520475
[TBL] [Abstract][Full Text] [Related]
58. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
[TBL] [Abstract][Full Text] [Related]
59. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
[TBL] [Abstract][Full Text] [Related]
60. Value of R2* obtained from T2*-weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy.
Li XS; Fan HX; Fang H; Song YL; Zhou CW
J Magn Reson Imaging; 2015 Sep; 42(3):681-8. PubMed ID: 25581675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
